Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 13, 2003. The report details specific corporate actions regarding share re-purchases and changes in directors' share interests, rather than providing comprehensive financial results for a fiscal period.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to specific share transactions:
- Share Re-purchase Price: 997.1663p per share.
- Director Share Purchase Price: £10.426 per share.
Material Changes
The filing reports the following material corporate actions:
- Share Re-purchase: The company purchased 2,785,000 ordinary shares for cancellation. This action was executed under authority granted by shareholders at the Annual General Meeting on May 20, 2002.
- Director's Interest Change: Director Mr. J.D. Coombe acquired 22 ordinary shares in total on March 11, 2003, through the Company's ShareReward Plan. This included 11 shares via personal contribution and 11 shares via company matching.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or details on unusual items. The document is strictly a notification of the share transactions described above.
Investor Verification Checklist
- Verify the total number of shares repurchased for cancellation (2,785,000) against the company's authorized buyback limit.
- Confirm the execution price of the buyback (997.1663p) relative to the market price on March 13, 2003.
- Review the terms of the ShareReward Plan to understand the matching contribution mechanism utilized by Mr. Coombe.
- Note that this filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F for comprehensive financial statements.